enGene reports FY2023 net loss $104.7M; Phase 1 LEGEND study 68% CR rate, interim data mid-2024

enGene Therapeutics Inc.

FY2023 net loss $104.7M ($151.22/share) vs $29.0M ($44.30) in FY2022; operating expenses $26.0M.
Phase 1 LEGEND study in BCG-unresponsive NMIBC met endpoints; 68% complete response at 3 months (n=22); pivotal Phase 2 enrolling, interim data mid-2024.
Completed reverse merger with FEAC and upsized PIPE financing, net proceeds ~$109M; launched on Nasdaq Nov 1, 2023.
Expanded Hercules debt facility to $50M ($22.5M funded); cash $81.5M at Oct 31, 2023, runway into Q2 2025.
Leadership hires: Alex Nichols (President/COO), Richard Bryce (CMO), Ryan Daws (CFO), Lota Zoth (Board).

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

enGene Therapeutics Inc. reported the fiscal year ended October 31, 2023 results: net income $104.7 million, EPS $151.22 per share.

Period: the fiscal year ended October 31, 2023
Net income: $104.7 million
EPS: $151.22 per share
Result: reported results

Exact text from the filing

For the full year 2023, net loss attributable to common shareholders was $104.7 million, or $151.22 per share, compared to $29.0 million, or $44.30 per share, for the same period in 2022.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

enGene Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-008123

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.